9 completed, 2 terminated, 1 recruiting, 1 unknown. 14 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 9, Terminated 2, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Postpartum Depression: new trials by email Literature Review of Postpartum Depression trials Research Report on Postpartum Depression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series interpersonal psychotherapy (IPT), Ketamine - Postpartum Depression | Phase 2 / Phase 3 | Withdrawn | Washington University School of Medicine | 2025-10-15 | 2025-10-29 | |
| Efficacy of MI078 Capsules in Treating Postpartum Depression MI078 capsule dose 1, MI078 capsule dose 2, placebo - Postpartum Depression | Phase 2 | Completed | Nanjing Minova Pharmaceutical Co., Ltd. | 72 | 2024-09-09 | 2026-06-25 |
| RE104 Safety and Efficacy Study in Postpartum Depression RE104 for Injection - Postpartum Depression | Phase 2 | Completed | Reunion Neuroscience Inc | 84 | 2024-06-14 | 2026-05-14 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression NORA520 Dose 1, NORA520 Dose 2, Placebo - Depression, Postpartum, Postpartum Depression | Phase 2 | Completed | TWi Biotechnology, Inc. | 93 | 2024-03-28 | 2026-07-31 |
| A Phase II Study of HS-10353 in Participants With Postpartum Depression HS-10353 Capsules 30 mg, Oral, QN for 14 days, HS-10353 Capsules 50 mg, Oral, QN for 14 days, HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days. - Postpartum Depression | Phase 2 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 96 | 2023-08-31 | 2023-07-10 |
| Phase 2 Clinical Trial of GH001 in Postpartum Depression GH001 - Postpartum Depression, Postnatal Depression | Phase 2 | Terminated | GH Research Ireland Limited | 10 | 2023-03-02 | 2025-02-18 |
| The SUPPORT Study: Effectiveness and Usability of a Web-Enabled Resource for Postpartum Mental Health Postpartumcare.ca (Web-Enabled Intervention) - Postpartum Depression, Postpartum Anxiety | Phase 2 | Completed | University of British Columbia | 103 | 2022-04-20 | 2023-05-10 |
| Maternal Mental Health Trial Transdermal patch estradiol, Transdermal patch placebo - Major Depressive Disorder, Postpartum Depression | Phase 1 / Phase 2 | Recruiting | Vibe G Frøkjær, MD, PhD | 220 | 2021-02-03 | 2021-09-23 |
| Ketamine to Improve Recovery After Cesarean Delivery - Part 1 Ketamine - Obstetric Pain, Postpartum Depression | Phase 2 | Completed | Grace Lim, MD, MS | 8 | 2019-10-09 | 2022-12-20 |
| Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression SAGE-547 - Postpartum Depression | Phase 2 | Completed | Supernus Pharmaceuticals, Inc. | 4 | 2015-01-07 | 2025-09-15 |
| The Effect of Exercise on Preventing PostPartum Depression Wellness Control, Exercise Intervention - PostPartum Depression | Phase 2 | Completed | University of Minnesota | 130 | 2009-09-01 | 2019-11-18 |
| Mom: Managing Our Mood, Part of The Family Help Program Distance Treatment for postpartum depression - Postpartum Depression | Phase 2 | Completed | IWK Health Centre | 62 | 2006-05-01 | 2016-09-02 |
| Clinical Trial of Estrogen for Postpartum Depression 17beta Estradiol, Placebos - Postpartum Depression, Depression | Phase 2 | Terminated | National Institute of Mental Health (NIMH) | 12 | 2003-04-17 | 2018-06-13 |
| The Role of Hormones in Postpartum Mood Disorders Estradiol, Placebo, Progesterone - Postpartum Depression | Phase 2 | Completed | National Institute of Mental Health (NIMH) | 74 | 1996-04-26 | 2025-12-05 |
Depression, Postpartum (14) · Depression (4) · Acute Pain (1) · Breast Feeding (1) · Chronic Pain (1) · Depressive Disorder, Major (1) · Labor Pain (1) · Motor Activity (1) · Puerperal Disorders (1)
Depressive Disorder (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Mental Disorders (14) · Mood Disorders (14) · Pregnancy Complications (14) · Urogenital Diseases (14) · Puerperal Disorders (13) · Behavior (6) · Behavioral Symptoms (4) · Feeding Behavior (1) · Neurologic Manifestations (1) · Pain (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Estradiol (2) · Ketamine (2) · Injections (1) · Interpersonal Psychotherapy (1) · Leuprolide (1) · Methoxydimethyltryptamines (1) · Progesterone (1) · adenylate isopentenyltransferase (1) · brexanolone (1)
National Institute of Mental Health (NIMH) (2) · GH Research Ireland Limited (1) · Grace Lim, MD, MS (1) · IWK Health Centre (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Nanjing Minova Pharmaceutical Co., Ltd. (1) · Reunion Neuroscience Inc (1) · Supernus Pharmaceuticals, Inc. (1) · TWi Biotechnology, Inc. (1) · University of British Columbia (1) · University of Minnesota (1) · Vibe G Frøkjær, MD, PhD (1) · Washington University School of Medicine (1)
United States (8) · Canada (2) · China (1) · Denmark (1) · Netherlands (1) · United Kingdom (1)
Peter J Schmidt, M.D. (2) · Beth A Lewis, PhD (1) · David Monks, MBCHB (1) · Grace Lim, MD, MS (1) · Jasna Hocevar-Trnka, M.D. (1) · Patrick J McGrath, PhD (1) · Stephen J Kanes, MD, PhD (1)
PMID 28480799, PMID 29316912, PMID 35763351, PMID 38709329, PMID 42247279
R21MH085176 (1)